|
William (Bill) Milligan
Senior Vice President of Corporate & Business Development
Steminent Biotherapeutics
Vancouver, BC
Canada
|
Milligan is a biologist / businessman educated at U. of Calgary (Biology) and Ryerson University (Business) with over 25 years of executive leadership experience in business / corporate development, product development, marketing, pricing, reimbursement, and financing in the biopharmaceutical industry across a range of companies, therapeutic technologies, disease states and regions. Prior to his Cell & Gene Therapy experience as SVP Corporate & Business Development, Steminent Biotherapeutics Inc.(Taiwan / USA) and VP Business Development, AventaCell Biomedical Co. (Taiwan / USA), Milligan served in the Biotech sector as: Chief Business Officer for Migenix Inc.(TSE:MGI (CAN)), CEO / Director for Cytran Inc.(USA): developing IV peptide therapeutics, and CEO / Director for Intellivax Inc.(USA) developing nasal vaccine candidates. In Pharma, his roles included VP Biomedical Division, VP Sales Division, and VP BD, Pricing & New Product Planning (Hoffman-La Roche), and Product Manager (Eli Lilly). Co-author of a number of publications in peer-reviewed journals, Milligan has also served as Director on multiple Biotech Boards during his career. Milligan is currently Chair: ISCT APAC Region Industry Committee, and has also served as Chair: ISCT Business Models and COG Committee (2013-2018), Chair: ISCT Strategies for Commercialization Organizing Committee (2018 AM Montreal & 2019 AM Melbourne), and Co-Chair: ISCT Business Models and Investment Committee (2018-2021). Detailed Bio: https://ca.linkedin.com/in/bill-milligan-051200b